Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Ptc Therapeutics (PTCT) Shares Outstanding (Weighted Average) (2016 - 2025)

Ptc Therapeutics (PTCT) has 12 years of Shares Outstanding (Weighted Average) data on record, last reported at $76.8 million in Q4 2024.

  • For Q4 2024, Shares Outstanding (Weighted Average) rose 2.68% year-over-year to $76.8 million; the TTM value through Dec 2024 reached $76.8 million, up 2.68%, while the annual FY2024 figure was $76.8 million, 2.68% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $76.8 million in Q4 2024 per PTCT's latest filing, roughly flat from $76.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $76.9 million in Q3 2024 and bottomed at $62.4 million in Q1 2020.
  • Average Shares Outstanding (Weighted Average) over 5 years is $71.6 million, with a median of $71.5 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Weighted Average): increased 17.03% in 2020, then rose 1.41% in 2022.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $66.0 million in 2020, then increased by 6.72% to $70.5 million in 2021, then rose by 1.79% to $71.7 million in 2022, then rose by 4.34% to $74.8 million in 2023, then increased by 2.68% to $76.8 million in 2024.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $76.8 million in Q4 2024, $76.9 million in Q3 2024, and $76.6 million in Q2 2024.